ManageChatDiscover
111014

Assessment of PD-L1 and p53 expression in urinary bladder carcinoma: Association with different clinicopathologic characteristics

Article

Last updated: 04 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

Anti-cancer Immunotherapy
Cellular and molecular targeting

Abstract

Background: Urinary bladder carcinoma is the most common urologic malignancy that includes phenotypically and genotypically diverse tumors. The development of new treatment modalities is essential to improve the outcomes and increase the overall survival of urinary bladder carcinoma patients'. Among these modalities, comes the PD-L1 inhibitors, as promising immunotherapy. P53 may also play a role in these treatment strategies. Aim: This study aimed to evaluate PD-L1 and p53 expression in urinary bladder carcinoma, and its available variants, and relate PD-L1 and p53 expression to each other and the available clinicopathological features. Materials and methods: This study included 60 cases of urinary bladder carcinoma, with no history of radiotherapy or chemotherapy, classified as follows: 32 cases of urothelial carcinoma, 25 squamous cell carcinomas, and 3 adenocarcinomas. Immunohistochemical staining of all cases using PD-L1 and p53 was done. Results: Positive PD-L1 expression was detected in 51.7% of all cases. PD-L1 expression was significantly associated with the histopathological types, high tumor grade and muscle invasion. High p53 expression was detected in 50% of the studied cases. P53 expression was significantly associated with high tumor grade, advanced stage, vascular invasion and lymph node metastasis. PD-L1 and p53 co-expression was detected in 33.3% of the cases. PD-L1 positivity was significantly associated with p53 expression. Conclusions: PD-L1 and p53 could be considered as predicting biomarkers for aggressive bladder carcinoma and their immunohistochemical expression may aid in identifying suitable patients for target therapy.

DOI

10.21608/jcbr.2020.35710.1054

Keywords

immune checkpoints, p53, PD-L1, Urinary Bladder Carcinoma

Authors

First Name

Nehal

Last Name

Heabah

MiddleName

A.

Affiliation

Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt

Email

nehalghaffar@yahoo.com

City

-

Orcid

0000-0002-0110-2709

First Name

Asmaa

Last Name

Bedeer

MiddleName

E.

Affiliation

Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt

Email

asmaa.bedeer@gmail.com

City

Tanta

Orcid

-

Volume

5

Article Issue

1

Related Issue

23533

Issue Date

2021-03-01

Receive Date

2020-07-14

Publish Date

2021-03-01

Page Start

15

Page End

26

Print ISSN

2682-261X

Online ISSN

2682-2628

Article File

JCBR_Volume 5_Issue 1_Pages 15-26.pdf

PDF . 3.8MB

Link

https://jcbr.journals.ekb.eg/article_111014.html

Detail API

https://jcbr.journals.ekb.eg/service?article_code=111014

Order

3

Type

Original Article

Type Code

885

Publication Type

Journal

Publication Title

International Journal of Cancer and Biomedical Research

Publication Link

https://jcbr.journals.ekb.eg/

MainTitle

Assessment of PD-L1 and p53 expression in urinary bladder carcinoma: Association with different clinicopathologic characteristics

Details

Type

Article

Created At

22 Jan 2023